- Transgender patients sue the hospital that provided their records to Tennessee’s attorney general ABC News
- Vanderbilt sued after turning over transgender health records to AG USA TODAY
- Patients sue Vanderbilt for releasing transgender clinic records to Tennessee AG – Tennessee Lookout Tennessee Lookout
- Transgender patients sue Vanderbilt over ‘serious harm’ from disclosed medical records WTVC
- Lawsuit: Vanderbilt University Medical Center ‘failed its patients’ in handing over trans health records News Channel 5 Nashville
- View Full Coverage on Google News
Tag Archives: patients
Feds warn hospitals not to divulge patients’ telehealth information – Scripps News
- Feds warn hospitals not to divulge patients’ telehealth information Scripps News
- FTC, HHS warn providers about privacy risks of tracking tech FierceHealthcare
- FTC, OCR caution hospitals and telehealth providers against using online tracking International Association of Privacy Professionals
- OCR and FTC Issue Joint Statement Warning Health Care Providers and App Developers About Use of Third Party Online Tracking Technologies Mintz
- FTC, OCR send warning letter to hospitals about online tracking pixels Healthcare IT News
- View Full Coverage on Google News
Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Shows Overall Survival and Progression-Free Survival Benefit for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma in the Phase 3 CheckMate -901 Trial – Bristol-Myers Squibb
- Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Shows Overall Survival and Progression-Free Survival Benefit for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma in the Phase 3 CheckMate -901 Trial Bristol-Myers Squibb
- Bristol Myers’ Opdivo stages comeback in bladder cancer, teeing up 2 ‘Merck’ showdowns FiercePharma
- Bristol Myers’ Opdivo extends survival in bladder cancer study Reuters
- First-line Nivolumab Plus Chemo Provides Survival Benefit in Metastatic Urothelial Carcinoma OncLive
- Study: Bladder Cancer Drug Extends Survival Newsmax
Millions of patients do not have full recovery of smell or taste senses after COVID infection, study finds – Medical Xpress
- Millions of patients do not have full recovery of smell or taste senses after COVID infection, study finds Medical Xpress
- One in Four COVID-19 Patients Struggle to Regain Sense of Taste and Smell Neuroscience News
- Millions of COVID patients still don’t have their sense of smell or taste, Mass Eye and Ear study finds Boston Herald
- Millions who had COVID still lack sense of taste or smell, study finds The Seattle Times
- Many adults infected with COVID-19 report only partial or no recovery of taste or smell News-Medical.Net
- View Full Coverage on Google News
AstraZeneca’s Tagrisso slashes death risk in certain post-surgery lung cancer patients – Reuters.com
- AstraZeneca’s Tagrisso slashes death risk in certain post-surgery lung cancer patients Reuters.com
- Lung cancer pill cuts risk of death by half, says ‘thrilling’ study The Guardian
- Stopping treatment at two years does not seem to compromise overall survival in patients with advanced lung cancer News-Medical.Net
- Game-Changer: Tagrisso May Reduce Risk of Death by Half in Some Early-Stage Lung Cancer Patients, ‘Compelling’ New Data Shows SurvivorNet
- ‘Extraordinary’ survival data for lung cancer patients is seen as boost for AstraZeneca drug STAT
- View Full Coverage on Google News
Novartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups – Novartis
- Novartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups Novartis
- Drug cuts risk of breast cancer recurrence for some early-stage patients, trial shows CNN
- Novartis drug cuts recurrence risk by 25% in early-stage breast cancer Reuters
- ASCO: Novartis details Kisqali’s adjuvant breast cancer win FiercePharma
- Breast cancer drug cuts risk of most common form returning by 25% The Guardian
- View Full Coverage on Google News
Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial – The Lancet
- Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial The Lancet
- Remote pulmonary artery pressure monitoring improves quality of life, reduces heart failure hospitalizations News-Medical.Net
- In early trial, drug appears to reduce harmful protein buildup in heart STAT
- Remote pulmonary artery pressure monitoring lowers hospitalisations for heart failure: Study ETHealthWorld
- Study shows potential benefit of sacubitril/valsartan in heart failure patients with EF over 40% News-Medical.Net
- View Full Coverage on Google News
Tagrisso plus chemotherapy demonstrated strong improvement in progression-free survival for patients with EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial – AstraZeneca
- Tagrisso plus chemotherapy demonstrated strong improvement in progression-free survival for patients with EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial AstraZeneca
- AstraZeneca Tagrisso chemo combo cuts risk of lung cancer progression Seeking Alpha
- Immunotherapy Plus Chemo Improves Quality of Life in NSCLC Medscape
- AstraZeneca’s Tagrisso, chemo combination shows promise in lung cancer trial Reuters
- Docetaxel Plus Ramucirumab After Standard Frontline Treatment Elicits Responses in NSCLC OncLive
- View Full Coverage on Google News
Repeated blood–brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial – The Lancet
- Repeated blood–brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial The Lancet
- Chemotherapy drug reaches brain in humans for first time Northwestern Now
- Northwestern team bypasses blood-brain barrier in brain cancer breakthrough Chicago Tribune
- Repeated blood–brain barrier opening with an implantable ultrasound device The Lancet
- Glioblastoma: Immunotherapy-loaded gel stops cancer in mice Medical News Today
- View Full Coverage on Google News
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet
- Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial The Lancet
- Merck clashes with AstraZeneca in biliary tract cancer FiercePharma
- AACR 2023 – more hope for Moderna’s neoantigen immunotherapy Evaluate Pharma
- Pembrolizumab Plus Gemcitabine/Cisplatin Provided Significant Improvement in OS in Advanced Biliary Tract Cancer Pharmacy Times
- Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melano Yahoo Finance
- View Full Coverage on Google News